We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $12.44 · 4 analysts
Stored first · Google News · Yahoo Finance (English)
Cross Country Healthcare Clears Key Hurdle as Stockholders Approve Merger - Yahoo Finance
Cross Country Healthcare Clears Key Hurdle as Stockholders Approve Merger Yahoo Finance
Cross Country Healthcare Clears Key Hurdle as Stockholders Approve Merger
Cross Country Healthcare Shareholders Approve Acquisition Proposal
Cross Country Healthcare (CCRN) investors approve take-private merger deal - Stock Titan
Cross Country Healthcare (CCRN) investors approve take-private merger deal Stock Titan
CCRN Stock Alert: Halper Sadeh LLC is Investigating Whether Cross Country Healthcare, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
CCRN Stock Alert: Halper Sadeh LLC is Investigating Whether Cross Country Healthcare, Inc. is Obtaining a Fair Price for its Shareholders Business Wire
CCRN Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Cross Country Healthcare to Knox Lane - marketscreener.com
CCRN Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Cross Country Healthcare to Knox Lane marketscreener.com
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | After market close (AMC) | $0.02 | — | — | $241.61M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.02 | — | — | $293.41M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.32 | — | — | $1.03B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.39 | — | — | $718.95M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 11. | Truist Securities | — | Maintain | Hold → Hold | — | Truist Securities: Hold |
| 2026. 05. 09. | Benchmark | — | Downgrade | Buy → Hold | — | Benchmark: Buy → Hold |
| 2026. 05. 07. | Wedbush | — | Downgrade | Outperform → Neutral | — | Wedbush: Outperform → Neutral |
| 2026. 03. 20. | Wedbush | — | Upgrade | Neutral → Outperform | — | Wedbush: Neutral → Outperform |
| 2026. 03. 06. | Benchmark | — | Upgrade | Hold → Buy | — | Benchmark: Hold → Buy |
| 2026. 02. 04. | Wedbush | — | Initiate coverage | — → Neutral | — | Wedbush: Neutral |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.